Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag was updated to v3.6.6 from v3.6.5, indicating a backend/template update; no study content or participant information appears to be changed.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor maintenance/metadata update rather than a change to core study content.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, indicating a new version of the study record. This change is administrative and does not alter the study details or participant-facing information.SummaryDifference0.1%

- Check73 days agoChange DetectedFooter area now includes new institutional attributions for the Moffitt Cancer Center Clinical Trials website and related entities, and the revision tag in the footer has been updated from v3.6.2 to v3.6.3.SummaryDifference0.2%

- Check80 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a recent deployment of the ClinicalTrials.gov page. This update does not change the study details or any data presented on the page.SummaryDifference0.1%

- Check94 days agoChange DetectedPage now displays a recruitment status indicating no longer looking for participants and adds new reader guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) to help users understand and engage with the study. The Intervention/Treatment label is reformatted, and the site revision is updated to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.